Evidence map›Paper›PMID 28404929›Full record

ArticleOncotarget2017

Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.

Xiao Jun Huang, Kaiyan Liu, David Ritchie, Borje Andersson, Jin Lu, Jian Hou, Adolfo de la Fuente Burguera, JianXiang Wang, Allen Yeoh, Chenhua Yan and 32 more

Abstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Myeloma at Cross Roads in India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

Xiao Jun HuangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Kaiyan LiuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
David RitchieRoyal Melbourne Hospital, Melbourne, Australia.
Borje AnderssonMD Anderson Cancer Center, Houston, Texas, USA.
Jin LuPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Jian HouShanghai Changzheng Hospital, Shanghai, China.
Adolfo de la Fuente BurgueraMD Anderson Cancer Center, Madrid, Spain.
JianXiang WangChinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Allen YeohNational University Hospital, Singapore.
Chenhua YanPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Daobin ZhouSeoul St. Mary's Hospital, S. Korea.
Daryl TanSingapore General Hospital, Singapore.
Dong Wook KimSeoul St. Mary's Hospital, S. Korea.
Depei WuFirst Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Jiangsu, China.
Elizabeth ShpallMD Anderson Cancer Center, Houston, Texas, USA.
Stephen KornblauMD Anderson Cancer Center, Houston, Texas, USA.
Sattava NeelapuMD Anderson Cancer Center, Houston, Texas, USA.
Suradej HongengRamathibodi Hospital, Bangkok, Thailand.
Jianyong LiFirst Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Jiong HuRuijin Hospital, Shanghai, China.
Lian Sheng ZhangGansu Provincial Key Laboratory of Hematology, Lanzhou, China.
Michael WangMD Anderson Cancer Center, Houston, Texas, USA.
Pankaj MalhotraPost Graduate Institute of Medical Education and Research, Chandigarh, India.
Qian JiangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Yazhen QinPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Raymond WongPrince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
Richard ChamplinMD Anderson Cancer Center, Houston, Texas, USA.
Frederick HagemeisterMD Anderson Cancer Center, Houston, Texas, USA.
Jason WestinMD Anderson Cancer Center, Houston, Texas, USA.
Swaminathan IyerMethodist Hospital, Houston, Texas, USA.
Vikram MathewsChristian Medical College and Hospital, Vellore, India.
Yu WangPeking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Yu HuWuhan Union Hospital, Wuhan, China.
Zhijian XiaoInstitute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences, Tianjin, China.
Zonghong ShaoGeneral Hospital of Tianjin Medical University, Tianjin, China.
Robert Z OrlowskiMD Anderson Cancer Center, Houston, Texas, USA.
Chor Sang ChimQueen Mary Hospital, Hong Kong.
Stephen MulliganRoyal North Shore Hospital, University of Sydney, Australia.
Miguel SanzUniversity Hospital La Fe, Valencia, Spain.
Keiya OzawaThe Institute of Medical Science, University of Tokyo, Japan.
Simrit ParmarMD Anderson Cancer Center, Houston, Texas, USA.
Surapol IssaragrisilFaculty of Medicine Siriraj Hospital, Bangkok, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report serves as a snapshot of the state-of-knowledge in the Asia Pacific (APAC) Hematology Oncology community, and establishes a baseline for longitudinal investigations to follow changes in best practices over time. The objective of this study was to understand the approach to hematologic diseases, common standards of care and best practices, issues that remain controversial or debated, and educational or resource gaps that warrant attention. We used mobile application to disseminate and distribute questionnaires to delegates during the 6th international hematologic malignancies conference hosted by the APAC Hematology Consortium at Beijing, China. User responses were collected in an anonymous fashion. We report survey results in two ways: the overall responses, and responses as stratified between Chinese physicians and "Other" represented nationalities. Overall geographical concordance in survey responses was positive and strong. Perhaps more interesting than instances of absolute agreement, these data provide a unique opportunity to identify topics in which physician knowledge or opinions diverge. We assigned questions from all modules to broad categories of: patient information; diagnosis; treatment preference; transplantation; and general knowledge/opinion. On average, we observed a geographic difference of 15% for any particular answer choice, and this was fairly constant across survey modules. These results reveal utility and need for widespread and ongoing initiatives to assess knowledge and provide evidence-based education in real time. The data will be made more valuable by longitudinal participation, such that we can monitor changes in the state of the art over time.

Indexed as

AsiaBeijingChinaHematologic NeoplasmsHematologyHumansMedical OncologyPractice Patterns, Physicians'Surveys and QuestionnairesAsiahematologyleukemialymphomamyeloma

Identifiers

PMID28404929
PMCPMC5522281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.